Investment view: Despite all the crowing, it pays to be cautious

GlaxoSmithKline Our view: Keep buying

Price: 1406.5p (-1.5p)

Astrazeneca Our view: Hold

Price: 2896.5p (+12p)

After the gloom of the double-dip recession, the Government was crowing yesterday thanks to the economy apparently roaring back with growth of 1 per cent in the third quarter. So, is it time to dive into the stock market for some of the more risky plays out there?

Certainly some investors did. The FTSE 100 reacted with a shrug of the shoulders to post a small gain, but these days it is an international index dependent on commodities, international finance and the like.

The FTSE 250 index of second-tier, much more UK-focused companies, posted a very solid gain, suggesting the market looked at the figures with starry eyes.

But there are grounds for caution. The GDP figure was flattered by a number of one-offs and confidence remains pretty fragile.

That's why I'm going to look at GlaxoSmithKline and AstraZeneca, generally considered defensive plays valued more for the ability to pay solid dividends than for runaway growth.

Astra, which posted third-quarter results yesterday, isn't quite as defensive as it once was. The Anglo-Swedish drugs group has been battered as patents have run out on key treatments with a lack of new innovations to replace them. Third-quarter sales fell to $6.2bn (£3.8bn) against $8.2bn for the same period in 2011. That's down by 19 per cent, 15 per cent after smoothing for currency fluctuations. Operating profits were also hit, coming in at $2.2bn from $4.3bn, a tumble of 49 per cent (47 per cent at constant currencies).

There were a couple of disposals, but the problem was that a number of key treatments no longer have patent protection in the lucrative US market.

While the numbers might look scary, the problem is priced into the shares, which trade on just 7.8 times this year's forecast earnings, while yielding a shade above 6 per cent. Even with the reduction in earnings, the payout is twice covered.

Astra, it's true, suspended plans for share buybacks to give it flexibility to do deals and buy more treatments, when Pascal Soriot was hired to replace the ousted David Brennan as chief executive. The good thing is most analysts believe the divvy is stable. And it's very attractive.

I'm usually wary of mergers and acquisitions, but Astra's could use a shot in the arm from somewhere. At the very beginning of July I said the innovative tie-up with US peer Bristol-Myers Squib for the £4.5bn takeover of US biotech Amylin, with its potential blockbuster diabetes drugs, made it worth a punt. At the time it stood at 2,882p. The shares are little changed since then. I'm inclined to stick with them, but wouldn't buy more until we've seen more detail on Mr Soriot's plans. Hold.

GlaxoSmithKline is in a much happierplace, with less of a reliance on blockbuster drugs and a useful place in the consumer healthcare business in emerging markets, where the demographics are very much in its favour.

The shares are down a shade from where I said buy at 1,427p on 17 April, despite a run of resilient financial statements which suggest that everything at GSK is running smoothly. Perhaps the explanation is that investors are shunning safe, boring-looking big pharma stocks like GSK in favour of more excitement. I can't blame them.

But I'm not convinced that either the British or the global economies are out of the woods. You only need another wobble in the eurozone, more stupidity in the US congress over that country's debt mountain, or any number of other possible shocks to knock things sideways.

As such, I'd want a quality, defensive, stock like GSK on my side. On 12 times this year's forecast earnings it's no screaming bargain. But quality costs money, and the 5 per cent forecast yield is well worth having.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Software Development Manager

£40000 - £50000 per annum: Recruitment Genius: This is an exciting opportunity...

Ashdown Group: Product Manager - (Product Marketing, Financial Services)

£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...

Recruitment Genius: Compliance Assistant

£13000 per annum: Recruitment Genius: This Pension Specialist was established ...

Ashdown Group: Market Research Executive

£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...

Day In a Page

As in 1942, Germany must show restraint over Greece

As in 1942, Germany must show restraint over Greece

Mussolini tried to warn his ally of the danger of bringing the country to its knees. So should we, says Patrick Cockburn
Britain's widening poverty gap should be causing outrage at the start of the election campaign

The short stroll that should be our walk of shame

Courting the global elite has failed to benefit Britain, as the vast disparity in wealth on display in the capital shows
Homeless Veterans appeal: The rise of the working poor: when having a job cannot prevent poverty

Homeless Veterans appeal

The rise of the working poor: when having a job cannot prevent poverty
Prince Charles the saviour of the nation? A new book highlights concerns about how political he will be when he eventually becomes king

Prince Charles the saviour of the nation?

A new book highlights concerns about how political he will be when he eventually becomes king
How books can defeat Isis: Patrick Cockburn was able to update his agenda-setting 'The Rise of Islamic State' while under attack in Baghdad

How books can defeat Isis

Patrick Cockburn was able to update his agenda-setting 'The Rise of Islamic State' while under attack in Baghdad
Judith Hackitt: The myths of elf 'n' safety

Judith Hackitt: The myths of elf 'n' safety

She may be in charge of minimising our risks of injury, but the chair of the Health and Safety Executive still wants children to be able to hurt themselves
The open loathing between Barack Obama and Benjamin Netanyahu just got worse

The open loathing between Obama and Netanyahu just got worse

The Israeli PM's relationship with the Obama has always been chilly, but going over the President's head on Iran will do him no favours, says Rupert Cornwell
French chefs get 'le huff' as nation slips down global cuisine rankings

French chefs get 'le huff' as nation slips down global cuisine rankings

Fury at British best restaurants survey sees French magazine produce a rival list
Star choreographer Matthew Bourne gives young carers a chance to perform at Sadler's Wells

Young carers to make dance debut

What happened when superstar choreographer Matthew Bourne encouraged 27 teenage carers to think about themselves for once?
Design Council's 70th anniversary: Four of the most intriguing prototypes from Ones to Watch

Design Council's 70th anniversary

Four of the most intriguing prototypes from Ones to Watch
Dame Harriet Walter: The actress on learning what it is to age, plastic surgery, and her unease at being honoured by the establishment

Dame Harriet Walter interview

The actress on learning what it is to age, plastic surgery, and her unease at being honoured by the establishment
Art should not be a slave to the ideas driving it

Art should not be a slave to the ideas driving it

Critics of Tom Stoppard's new play seem to agree that cerebral can never trump character, says DJ Taylor
Bill Granger recipes: Our chef's winter salads will make you feel energised through February

Bill Granger's winter salads

Salads aren't just a bit on the side, says our chef - their crunch, colour and natural goodness are perfect for a midwinter pick-me-up
England vs Wales: Cool head George Ford ready to put out dragon fire

George Ford: Cool head ready to put out dragon fire

No 10’s calmness under pressure will be key for England in Cardiff
Michael Calvin: Time for Old Firm to put aside bigotry and forge new links

Michael Calvin's Last Word

Time for Old Firm to put aside bigotry and forge new links